* Common neuropsychiatric symptoms included headaches (50.3%), seizures (38.3%), and acute confusional states (33.6%), with five distinct clusters of symptoms identified based on their clinical and laboratory findings.
* Key factors associated with increased risk of neurologic issues included positivity for antiphospholipid antibodies, history of plasmapheresis treatment, and higher SLEDAI scores, providing insights for better diagnosis and management.
* In the analysis, 15.9% of PID patients had autoimmune disorders, with a greater incidence in those with immune dysregulation, while 5.1% exhibited autoinflammation-related conditions.
* The findings emphasize the need for heightened awareness of the link between PID, autoimmunity, and autoinflammation, which can aid in timely diagnosis and management of these diseases.